Leadership · 4 min read
Health Economics in Orthopaedics: Understanding Value to Make Better Decisions
Every orthopaedic decision has an economic dimension — not as the primary consideration, but as an unavoidable one. The surgeon who understands health economics is better equipped to advocate for their patients, to evaluate new technologies honestly, and to contribute meaningfully to the resource allocation decisions that affect the care their entire patient population receives.
Health economics is not about rationing care or reducing treatment to financial calculation. It is the discipline that provides the analytical tools to assess whether the health gains produced by a clinical intervention justify the resources it consumes — and therefore whether those resources, in a world of finite healthcare budgets, are best used for this intervention or for another that produces greater benefit. This framework is relevant to every clinical decision, whether the clinician is aware of it or not.
The QALY and its clinical relevance
The quality-adjusted life year — the QALY — is the unit of health gain most commonly used in UK health technology assessment. It integrates two dimensions: survival (additional years of life) and health-related quality of life during those years, measured on a utility scale where full health equals 1.0 and death equals 0. An intervention that produces one additional year of perfect health generates one QALY; one that produces two years of health at 0.5 utility generates one QALY equivalently. NICE's threshold — the willingness-to-pay threshold below which interventions are generally considered cost-effective — sits at approximately £20,000–30,000 per QALY gained, though this threshold is applied with judgment rather than mechanically.
For orthopaedic procedures, the cost-effectiveness evidence is generally favourable: total hip and knee arthroplasty consistently produce QALYs at costs well within NICE thresholds, making them among the most cost-effective interventions in elective medicine. Shoulder arthroplasty, rotator cuff repair, and carpal tunnel decompression all have economic evidence bases that support their clinical uptake. Where the economic case is less well-established — new implant technologies, biological augmentation strategies, robotic assistance — understanding the cost-effectiveness framework enables a more sophisticated evaluation of vendor claims and commissioner concerns.
Budget impact vs cost-effectiveness
Cost-effectiveness and budget impact are distinct concepts that clinicians routinely conflate. A highly cost-effective intervention — one that produces health gain efficiently — may nonetheless have significant budget impact if it is applicable to a large population. Commissioners concerned about budget impact are not necessarily opposing cost-effective care; they are managing the implementation of cost-effective care within finite budget constraints. Understanding this distinction enables more productive dialogue between clinicians and healthcare commissioners.
The clinician who understands health economics can advocate for their patients with the language of resource allocation — and that advocacy is more effective than the language of clinical preference alone.
💬 Has health economic evidence — NICE appraisals, cost-effectiveness analyses — directly influenced a technology adoption or service redesign decision in your department?